Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating reaffirmed by Barclays in a research report issued to clients and investors on Wednesday. They currently have a $32.00 price target on the medical equipment provider’s stock. Barclays’ price target would suggest a potential upside of 16.47% from the company’s previous close.

Other research analysts have also issued research reports about the company. BMO Capital Markets restated a “buy” rating and set a $30.00 target price on shares of Boston Scientific in a research report on Friday, October 13th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research report on Tuesday, October 3rd. SunTrust Banks restated a “buy” rating and set a $34.00 target price on shares of Boston Scientific in a research report on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research report on Monday, September 25th. Finally, Canaccord Genuity dropped their target price on Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $31.00.

Boston Scientific (NYSE BSX) traded down $0.48 on Wednesday, reaching $27.48. The company had a trading volume of 7,164,482 shares, compared to its average volume of 12,757,684. Boston Scientific has a 12 month low of $22.19 and a 12 month high of $29.93. The stock has a market capitalization of $37,790.00, a price-to-earnings ratio of 45.04, a P/E/G ratio of 1.82 and a beta of 0.96. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the business earned $0.27 earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. analysts predict that Boston Scientific will post 1.25 earnings per share for the current year.

In related news, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was purchased at an average price of $0.45 per share, with a total value of $183,602.70. Also, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total transaction of $282,200.00. Following the sale, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at approximately $4,647,297.82. The disclosure for this sale can be found here. Insiders have sold 82,670 shares of company stock valued at $2,196,008 in the last ninety days. Insiders own 0.74% of the company’s stock.

Large investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC bought a new position in Boston Scientific in the third quarter worth approximately $138,000. Steward Partners Investment Advisory LLC bought a new position in Boston Scientific in the third quarter worth approximately $139,000. Acrospire Investment Management LLC raised its stake in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 3,100 shares in the last quarter. San Francisco Sentry Investment Group CA bought a new position in Boston Scientific in the second quarter worth approximately $191,000. Finally, Ironwood Investment Counsel LLC bought a new position in Boston Scientific in the third quarter worth approximately $204,000. 90.36% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/10/barclays-reiterates-buy-rating-for-boston-scientific-bsx.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related stocks with our FREE daily email newsletter.